FOURTH QUARTER OCTOBER-DECEMBER
- The Group's net sales amounted to
SEK 322.8 (257.9) million, an increase of 25 percent. -
The Group's EBITDA was
SEK 73.3 (66.5) million, an increase of 10 percent. Adjusted for items affecting comparability*), the increase was 16 percent. - The EBITDA margin was 23 (26) percent. Adjusted for items affecting comparability*), the margin was 23 (24) percent.
-
Profit after tax amounted to
SEK 40.5 (40.8) million. -
Earnings per share amounted to
SEK 2.7 (2.7). -
Cash flow from operating activities was
SEK -39.1 (42.6) million. Adjusted for the advance of approximatelySEK 115 million paid for shares inAdderaCare , cash flow from operating activities amounts toSEK 75.7 million .
TWELVE MONTHS JANUARY-DECEMBER
- The Group's net sales amounted to
SEK 1,111.3 (916.3) million, an increase of 21 percent. -
The Group's EBITDA was
SEK 258.7 (202.5) million, an increase of 28 percent. Adjusted for items affecting comparability*), the increase was 27 percent. - The EBITDA margin was 23 (22) percent. Adjusted for items affecting comparability*), the margin was 21 (20) percent.
-
Profit after tax amounted to
SEK 118.0 (98.1) million. -
Earnings per share amounted to
SEK 7.9 (6.5). -
Cash flow from operating activities was
SEK 85.5 (116.3) million. Adjusted for the advance of approximatelySEK 115 million paid for shares inAdderaCare , cash flow from operating activities amounts toSEK 200.3 million .
Fourth quarter
Sales were very strong in the fourth quarter and the Group grew by 25 percent. There is often slightly higher demand in the fourth quarter than the other quarters, as was also the case this year. The continued positive development in the fourth quarter contributed to annual growth of 21 percent. Growth is largely organic and demand for our products is strong. The companies have been able to meet demand and increase deliveries.
The Specialty Pharma business area continued to perform well in the fourth quarter and sales increased as a result of contracts awarded and continued growth in launched pharmaceuticals.
The
The Group's EBITDA increased by 16 percent, adjusted for items affecting comparability. Sales mix and, to some extent, the cost increases contributed to a slightly lower gross margin. Expenses increased, driven in part by personnel costs, marketing and development activities and acquisition-driven expenses.
Growth through acquisitions and active ownership
During the quarter,
By
In summary
The fourth quarter was the strongest ever and ended a very good year for the Group. Even after the acquisition of
I look forward to the journey ahead.
This disclosure contains information that
For more information, contact:
About
https://news.cision.com/medcap-ab/r/strong-organic-growth-in-both-the-quarter-and-the-year,c3712377
https://mb.cision.com/Main/2678/3712377/1839608.pdf
https://news.cision.com/medcap-ab/i/bild-anders,c3142826
(c) 2023 Cision. All rights reserved., source